



Fast-growing global biopharmaceuticals company & leading provider of affordable medicines



Diversified portfolio of 290+ products across Specialty, Biosimilars, Injectables and Retail Generics



Expansive R&D, manufacturing and commercial capabilities at scale with vertical integration



Robust R&D engine generating 20-30 new retail and injectables product launches consistently per year; focused on high-value, complex products



Accelerated revenue and profit growth outlook with higher cash flow generation and continued deleveraging

Diversified portfolio delivering sustainable growth...



Retail Generics

#4 U.S Generics portfolio, shift to complex dosage forms



Injectables

Expanding portfolio of 40+ institutional products with new differentiated 505(b)(2) injectables for hospitals



Biosimilars

Drive uptake of 3 commercial biosimilars and expand portfolio with next 5 biosimilars



AvKARE

Expanding presence across channels & dosage forms



Specialty

Branded therapies focused on Neurology and Endocrinology - highlighted by CREXTONT® for PD




International

Market expansion in India, Europe & rest of world

Adjusted EBITDA growth

\$ in millions



Financials

\$3.05B - 3.15B

+1 to 4% Growth 2026
Net Revenue guidance

\$720M - 760M

+5 to 10% Growth 2026
Adj. EBITDA guidance

3.5X

Net leverage as of
December 31, 2025

NASDAQ

AMRX



All data as of February 27, 2026.
1. Reflects 2026 guidance as of February 27, 2026. Full year 2026 estimates are based on management's expectations for prescription trends, pricing levels, inventory levels, the costs incurred and benefits realized of restructuring activities and the anticipated timing of future product launches and events, among other factors. Adjusted EBITDA is a non-GAAP measure; a discussion of Non-GAAP measures is included in the press release issued on February 27, 2026, available at <https://investors.amneal.com/news/press-releases/>.